FulvestrantRecent, repeatedEvidence- NCT07861932 · KymaThera, Inc. · Phase 2 · live · background · “Fulvestrant” · registered Sep 2026
- NCT07811232 · Advenchen Pharmaceuticals, LLC. · Phase 2 · live · background · “Fulvestrant” · registered Aug 2026
- NCT07748208 · Hoffmann-La Roche · Phase 2 · live · background · “Fulvestrant” · registered Jul 2026
- NCT07679269 · Novartis · Phase 2 · live · background · “Fulvestrant” · registered Jun 2026
- NCT07570966 · Novartis · Phase 2 · background · “Fulvestrant” · registered Apr 2026
| AstraZeneca70% of its industry studiesUS: off-patent, 11 generics marketedEU: off-patent, 1 generic authorized | 3050 studies | 3059 studies | background 86 · comparator 14 |
CapecitabineRecent, repeatedEvidence- NCT07824869 · Fosun Pharma · Phase 2 · live · background · “Capecitabine” · registered Sep 2026
- NCT07684456 · Beijing Biostar Pharmaceuticals Co., Ltd. · Phase 3 · live · background · “Capecitabine” · registered Jun 2026
- NCT07648914 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Capecitabine” · registered Jun 2026
- NCT07461454 · MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3 · live · comparator · “Capecitabine” · registered Mar 2026
- NCT07060807 · Merck & Co., Inc · Phase 3 · live · comparator · “Capecitabine” · registered Jul 2025
| Hoffmann-La Roche33% of its industry studiesEU: off-patent, 4 generics authorized | 2130 studies | 2134 studies | background 40 · comparator 49 |
TrastuzumabRecent, repeatedEvidence- NCT07824869 · Fosun Pharma · Phase 2 · live · background · “Trastuzumab” · registered Sep 2026
- NCT07683754 · Daiichi Sankyo · Phase 3 · live · background · “Trastuzumab” · registered Jun 2026
- NCT07679269 · Novartis · Phase 2 · live · background · “Trastuzumab” · registered Jun 2026
- NCT07545044 · CSPC Pharmaceutical Group Limited · Phase 2 · live · comparator · “Trastuzumab” · registered Apr 2026
- NCT07518173 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Trastuzumab” · registered Apr 2026
| Hoffmann-La Roche55% of its industry studiesUS: Hoffmann-La Roche (FDA 1998) + 6 othersEU: Hoffmann-La Roche (EMA 2000) + 8 others | 1930 studies | 1730 studies | comparator 40 · background 60 |
PaclitaxelRecent, repeatedEvidence- NCT07824869 · Fosun Pharma · Phase 2 · live · background · “Paclitaxel” · registered Sep 2026
- NCT07648914 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Paclitaxel” · registered Jun 2026
- NCT07377643 · Innovent Biologics, Inc. · Phase 3 · live · comparator · “Paclitaxel” · registered Jan 2026
- NCT07060807 · Merck & Co., Inc · Phase 3 · live · comparator · “Paclitaxel” · registered Jul 2025
- NCT07071337 · Sichuan Kelun Pharmaceutical Co.,Ltd. · Phase 3 · live · comparator · “Paclitaxel” · registered Jun 2025
| Hoffmann-La Roche12% of its industry studiesUS: off-patent, 10 generics marketed | 1724 studies | 1629 studies | background 83 · comparator 31 |
DocetaxelRecent, repeatedEvidence- NCT07824869 · Fosun Pharma · Phase 2 · live · background · “Docetaxel” · registered Sep 2026
- NCT07545044 · CSPC Pharmaceutical Group Limited · Phase 2 · live · comparator · “Docetaxel” · registered Apr 2026
- NCT07518173 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Docetaxel” · registered Apr 2026
- NCT07441460 · CSPC Pharmaceutical Group Limited · Phase 3 · live · comparator · “Docetaxel” · registered Feb 2026
- NCT07377643 · Innovent Biologics, Inc. · Phase 3 · live · comparator · “Docetaxel” · registered Jan 2026
| Sanofi27% of its industry studiesUS: off-patent, 13 generics marketedEU: off-patent, 2 generics authorized | 1422 studies | 1219 studies | background 55 · comparator 28 |
pertuzumabRecent, repeatedEvidence- NCT07683754 · Daiichi Sankyo · Phase 3 · live · background · “Pertuzumab” · registered Jun 2026
- NCT07679269 · Novartis · Phase 2 · live · background · “Pertuzumab” · registered Jun 2026
- NCT07545044 · CSPC Pharmaceutical Group Limited · Phase 2 · live · comparator · “Pertuzumab” · registered Apr 2026
- NCT07518173 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · background · “Pertuzumab” · registered Apr 2026
- NCT07441460 · CSPC Pharmaceutical Group Limited · Phase 3 · live · comparator · “Pertuzumab” · registered Feb 2026
| Hoffmann-La Roche73% of its industry studiesUS: Hoffmann-La Roche (FDA 2012)EU: Hoffmann-La Roche (EMA 2013) + 1 other | 1322 studies | 1525 studies | comparator 9 · background 20 |
CarboplatinRecent, repeatedPhase 4 trial recordedEvidence- NCT07441460 · CSPC Pharmaceutical Group Limited · Phase 3 · live · background · “Carboplatin” · registered Feb 2026
- NCT07287995 · Astellas Pharma Inc · Phase 2 · live · background · “Carboplatin” · registered Dec 2025
- NCT07196774 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Carboplatin for Injection” · registered Sep 2025
- NCT07173751 · BioNTech SE · Phase 3 · live · background · “Carboplatin” · registered Sep 2025
- NCT07043725 · Sino Biopharmaceutical Limited · Phase 3 · live · comparator · “Trastuzumab injection and Pertuzumab Injection and Docetaxel Injection and Carboplatin Injection” · registered Jun 2025
| Eli Lilly and Company16% of its industry studies | 1318 studies | 1419 studies | background 23 · comparator 10 |
exemestaneRecent, repeatedEvidence- NCT07937605 · Beijing Konruns Pharmaceutical Co., Ltd. · Phase 2 · live · background · “Exemestane” · registered Nov 2026
- NCT07935317 · Eli Lilly and Company · Phase 2 · live · background · “Exemestane” · registered Nov 2026
- NCT07349069 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Exemestane tablets” · registered Jan 2026
- NCT07024173 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Exemestane tablets” · registered Jun 2025
- NCT06957379 · CSPC Pharmaceutical Group Limited · Phase 2 · live · background · “Exemestane” · registered Apr 2025
| Pfizer60% of its industry studiesUS: off-patent, 7 generics marketed | 1318 studies | 1320 studies | background 32 · comparator 19 |
eribulinRecent, repeatedEvidence- NCT07824869 · Fosun Pharma · Phase 2 · live · background · “Eribulin” · registered Sep 2026
- NCT07811232 · Advenchen Pharmaceuticals, LLC. · Phase 2 · live · background · “Eribulin” · registered Aug 2026
- NCT07461454 · MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3 · live · comparator · “Eribulin” · registered Mar 2026
- NCT07173751 · BioNTech SE · Phase 3 · live · background · “Eribulin” · registered Sep 2025
- NCT07007559 · ALX Oncology Inc. · Phase 2 · live · background · “Eribulin” · registered May 2025
| Eisai Co., Ltd.87% of its industry studiesUS: off-patent, 10 generics marketedEU: off-patent, 2 generics authorized | 1213 studies | 1214 studies | background 10 · comparator 12 |
GemcitabineRecent, repeatedEvidence- NCT07461454 · MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3 · live · comparator · “Gemcitabine” · registered Mar 2026
- NCT07173751 · BioNTech SE · Phase 3 · live · background · “Gemcitabine” · registered Sep 2025
- NCT07007559 · ALX Oncology Inc. · Phase 2 · live · background · “Gemcitabine” · registered May 2025
- NCT06926868 · Bristol-Myers Squibb · Phase 3 · live · comparator · “Gemcitabine” · registered Apr 2025
- NCT06435429 · Jazz Pharmaceuticals · Phase 3 · live · background · “Gemcitabine” · registered May 2024
| Eli Lilly and Company30% of its industry studiesUS: off-patent, 11 generics marketed | 1111 studies | 1314 studies | background 12 · comparator 15 |
LetrozoleRecent, repeatedEvidence- NCT07935317 · Eli Lilly and Company · Phase 2 · live · background · “Letrozole” · registered Nov 2026
- NCT07492641 · BeOne Medicines · Phase 3 · live · background · “Letrozole” · registered Mar 2026
- NCT07389733 · Jiangsu HengRui Medicine Co., Ltd. · Phase 2 · live · background · “Letrozole tablets” · registered Jan 2026
- NCT07349069 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Letrozole tablets” · registered Jan 2026
- NCT07174336 · Eli Lilly and Company · Phase 3 · live · background · “Letrozole” · registered Sep 2025
| Novartis52% of its industry studiesUS: off-patent, 6 generics marketed | 1023 studies | 1128 studies | background 36 · comparator 17 |
Albumin-Bound PaclitaxelRecent, repeatedEvidence- NCT07738341 · Eddingpharm (Zhuhai) Co., Ltd. · Phase 2 · live · background · “Nab-Paclitaxel” · registered Jul 2026
- NCT07648914 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Albumin-Bound Paclitaxel” · registered Jun 2026
- NCT07060807 · Merck & Co., Inc · Phase 3 · live · comparator · “Nab-paclitaxel” · registered Jul 2025
- NCT07071337 · Sichuan Kelun Pharmaceutical Co.,Ltd. · Phase 3 · live · comparator · “Nab-paclitaxel” · registered Jun 2025
- NCT06312176 · Merck & Co., Inc · Phase 3 · live · comparator · “Nab-paclitaxel” · registered Mar 2024
| Bristol-Myers Squibb43% of its industry studiesEU: Bristol-Myers Squibb (EMA 2008) | 1012 studies | 1115 studies | comparator 12 · background 14 |
palbociclibRecent, repeatedEvidence- NCT07861932 · KymaThera, Inc. · Phase 2 · live · background · “Palbociclib” · registered Sep 2026
- NCT07748208 · Hoffmann-La Roche · Phase 2 · live · background · “Palbociclib” · registered Jul 2026
- NCT07683754 · Daiichi Sankyo · Phase 3 · live · background · “Palbociclib” · registered Jun 2026
- NCT07492641 · BeOne Medicines · Phase 3 · live · comparator · “Palbociclib” · registered Mar 2026
- NCT07002177 · forward pharmaceuticals co ltd · Phase 2 · live · background · “Palbociclib 125mg” · registered May 2025
| Pfizer81% of its industry studiesUS: Pfizer (FDA 2015)EU: off-patent, 1 generic authorized | 1012 studies | 1017 studies | background 24 · comparator 1 |
abemaciclibRecent, repeatedEvidence- NCT07492641 · BeOne Medicines · Phase 3 · live · comparator · “Abemaciclib” · registered Mar 2026
- NCT07100106 · Hoffmann-La Roche · Phase 2 · live · comparator · “Abemaciclib” · registered Jul 2025
- NCT07002177 · forward pharmaceuticals co ltd · Phase 2 · live · background · “Abemaciclib 150 MG” · registered May 2025
- NCT06760637 · Pfizer · Phase 3 · live · comparator · “abemaciclib” · registered Dec 2024
- NCT06380751 · AstraZeneca · Phase 3 · live · background · “Abemaciclib” · registered Mar 2024
| Eli Lilly and Company98% of its industry studiesUS: Eli Lilly and Company (FDA 2017)EU: Eli Lilly and Company (EMA 2018) | 1015 studies | 1018 studies | background 18 · comparator 3 |
VinorelbineRecent, repeatedPhase 4 trial recordedEvidence- NCT07824869 · Fosun Pharma · Phase 2 · live · background · “Vinorelbine” · registered Sep 2026
- NCT07461454 · MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3 · live · comparator · “Vinorelbine” · registered Mar 2026
- NCT07007559 · ALX Oncology Inc. · Phase 2 · live · background · “Vinorelbine” · registered May 2025
- NCT06435429 · Jazz Pharmaceuticals · Phase 3 · live · background · “Vinorelbine” · registered May 2024
- NCT06202261 · Sino Biopharmaceutical Limited · Phase 2 · live · background · “Vinorelbine tartrate injection” · registered Jan 2024
| Eli Lilly and Company9% of its industry studies | 99 studies | 1212 studies | background 12 · comparator 15 |
pembrolizumabRecent, repeatedEvidence- NCT07287995 · Astellas Pharma Inc · Phase 2 · live · background · “Pembrolizumab” · registered Dec 2025
- NCT07287917 · Aminex Therapeutics, Inc. · Phase 2 · live · background · “Pembrolizumab” · registered Nov 2025
- NCT06942234 · Alphamab Oncology · Phase 2 · live · background · “Pembrolizumab” · registered Apr 2025
- NCT06618287 · Bristol-Myers Squibb · Phase 2 · live · background · “Pembrolizumab” · registered Sep 2024
- NCT06253871 · Iambic Therapeutics, Inc · Phase 2 · live · background · “Oral treatment with IAM1363 capsules or tablets, administered in combination with pembrolizumab +/- carboplatin +/- pemetrexed” · registered Feb 2024
| Merck & Co., Inc74% of its industry studiesUS: Merck & Co., Inc (FDA 2014)EU: Merck & Co., Inc (EMA 2015) | 911 studies | 911 studies | background 14 · comparator 4 |
EverolimusRecent, repeatedEvidence- NCT07937605 · Beijing Konruns Pharmaceutical Co., Ltd. · Phase 2 · live · background · “Everolimus (10 mg QD)” · registered Nov 2026
- NCT07024173 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Everolimus Tablets” · registered Jun 2025
- NCT07002177 · forward pharmaceuticals co ltd · Phase 2 · live · background · “Everolimus 10 mg” · registered May 2025
- NCT06680921 · Simcere Pharmaceutical Group Limited · Phase 3 · live · background · “Everolimus (Afinitor®)” · registered Nov 2024
- NCT06428396 · Merck & Co., Inc · Phase 2 · live · comparator · “Everolimus” · registered May 2024
| Novartis92% of its industry studiesUS: off-patent, 14 generics marketedEU: Novartis (EMA 2009) | 99 studies | 99 studies | background 9 · comparator 3 |
ribociclibRecent, repeatedEvidence- NCT07647328 · AstraZeneca · Phase 3 · live · background · “Ribociclib” · registered May 2026
- NCT07492641 · BeOne Medicines · Phase 3 · live · comparator · “Ribociclib” · registered Mar 2026
- NCT07405801 · Hoffmann-La Roche · Phase 2 · live · background · “Ribociclib” · registered Feb 2026
- NCT07174336 · Eli Lilly and Company · Phase 3 · live · background · “Ribociclib” · registered Sep 2025
- NCT07054190 · Hoffmann-La Roche · Phase 2 · live · background · “Ribociclib” · registered Jun 2025
| Novartis87% of its industry studiesUS: Novartis (FDA 2017)EU: Novartis (EMA 2017) | 915 studies | 917 studies | background 15 · comparator 3 |
Ado-Trastuzumab EmtansineRecent, repeatedEvidence- NCT07673029 · GeneQuantum Healthcare (Suzhou) Co., Ltd. · Phase 3 · live · comparator · “T-DM1” · registered Jun 2026
- NCT07008976 · Sino Biopharmaceutical Limited · Phase 3 · live · comparator · “Trastuzumab Emtansine for Injection” · registered May 2025
- NCT06968585 · Sichuan Kelun Pharmaceutical Co.,Ltd. · Phase 3 · live · comparator · “T-DM1” · registered Apr 2025
- NCT06830889 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “T-DM1” · registered Feb 2025
- NCT06846437 · CSPC Pharmaceutical Group Limited · Phase 3 · live · comparator · “Trastuzumab emtansine (T-DM1)” · registered Jan 2025
| Hoffmann-La Roche100% of its industry studiesUS: Hoffmann-La Roche (FDA 2013)EU: Hoffmann-La Roche (EMA 2013) | 810 studies | 1012 studies | background 2 · comparator 12 |
AnastrozoleRecent, repeatedEvidence- NCT07935317 · Eli Lilly and Company · Phase 2 · live · background · “Anastrozole” · registered Nov 2026
- NCT07349069 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Anastrozole Tablets” · registered Jan 2026
- NCT07174336 · Eli Lilly and Company · Phase 3 · live · background · “Anastrozole” · registered Sep 2025
- NCT07024173 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Anastrozole Tablets” · registered Jun 2025
- NCT06957379 · CSPC Pharmaceutical Group Limited · Phase 2 · live · background · “Anastrozole” · registered Apr 2025
| AstraZeneca66% of its industry studiesUS: off-patent, 6 generics marketed | 812 studies | 714 studies | background 17 · comparator 10 |
CyclophosphamideRecent, repeatedEvidence- NCT07441460 · CSPC Pharmaceutical Group Limited · Phase 3 · live · background · “Cyclophosphamide” · registered Feb 2026
- NCT06966700 · Merck & Co., Inc · Phase 3 · live · comparator · “Cyclophosphamide” · registered May 2025
- NCT06829199 · Merck & Co., Inc · Phase 2 · background · “Cyclophosphamide” · registered Feb 2025
- NCT06797635 · Merck & Co., Inc · Phase 2 · live · comparator · “Cyclophosphamide” · registered Jan 2025
- NCT06389006 · RemeGen Co., Ltd. · Phase 2 · live · background · “Cyclophosphamide” · registered Apr 2024
| Hoffmann-La Roche13% of its industry studiesUS: off-patent, 12 generics marketed | 79 studies | 58 studies | comparator 6 · background 39 |
TamoxifenRecent, repeatedEvidence- NCT07349069 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Tamoxifen Citrate Tablets” · registered Jan 2026
- NCT07287098 · Eli Lilly and Company · Phase 2 · live · comparator · “Tamoxifen 20 mg” · registered Dec 2025
- NCT06449027 · Changchun GeneScience Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Leuprorelin Acetate Microspheres for Injection” · registered May 2024
- NCT05768139 · Eli Lilly and Company · Phase 2 · live · background · “Tamoxifen” · registered Mar 2023
- NCT05645536 · Tolmar Inc. · Phase 3 · live · background · “Tamoxifen” · registered Dec 2022
| AstraZeneca38% of its industry studiesUS: off-patent, 4 generics marketed | 68 studies | 710 studies | background 11 · comparator 10 |
trastuzumab deruxtecanRecent, repeatedEvidence- NCT07678957 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 2 · live · comparator · “DS-8201” · registered Jun 2026
- NCT07497386 · Jiangsu HengRui Medicine Co., Ltd. · Phase 2 · live · comparator · “Trastuzumab Deruxtecan for Injection” · registered Mar 2026
- NCT07294508 · Fosun Pharma · Phase 3 · live · background · “T-Dxd + Pertuzumab” · registered Dec 2025
- NCT06832202 · Fosun Pharma · Phase 2 · live · background · “Trastuzumab Deruxtecan” · registered Feb 2025
- NCT06324357 · Boehringer Ingelheim · Phase 2 · live · background · “Trastuzumab deruxtecan” · registered Mar 2024
| Daiichi Sankyo53% of its industry studiesUS: Daiichi Sankyo (FDA 2019)EU: Daiichi Sankyo (EMA 2021) | 67 studies | 79 studies | background 8 · comparator 2 |
EpirubicinRecent, repeatedEvidence- NCT07441460 · CSPC Pharmaceutical Group Limited · Phase 3 · live · background · “Epirubicin” · registered Feb 2026
- NCT06966700 · Merck & Co., Inc · Phase 3 · live · comparator · “Epirubicin” · registered May 2025
- NCT06829199 · Merck & Co., Inc · Phase 2 · background · “Epirubicin Hydrochloride” · registered Feb 2025
- NCT06797635 · Merck & Co., Inc · Phase 2 · live · comparator · “Epirubicin hydrochloride” · registered Jan 2025
- NCT06389006 · RemeGen Co., Ltd. · Phase 2 · live · background · “Epirubicin” · registered Apr 2024
| GlaxoSmithKline33% of its industry studiesUS: Pfizer (FDA 1999) | 47 studies | 47 studies | comparator 4 · background 14 |
DoxorubicinRecent, repeatedEvidence- NCT07441460 · CSPC Pharmaceutical Group Limited · Phase 3 · live · background · “Doxorubicin” · registered Feb 2026
- NCT06966700 · Merck & Co., Inc · Phase 3 · live · comparator · “Doxorubicin” · registered May 2025
- NCT06829199 · Merck & Co., Inc · Phase 2 · background · “Doxorubicin (hydrochloride)” · registered Feb 2025
- NCT06797635 · Merck & Co., Inc · Phase 2 · live · comparator · “Doxorubicin hydrochloride” · registered Jan 2025
- NCT06112379 · AstraZeneca · Phase 3 · live · comparator · “Doxorubicin” · registered Oct 2023
| Hoffmann-La Roche10% of its industry studiesUS: off-patent, 14 generics marketed | 46 studies | 36 studies | comparator 6 · background 21 |
GoserelinRecent, repeatedEvidence- NCT07287098 · Eli Lilly and Company · Phase 2 · live · background · “Goserelin” · registered Dec 2025
- NCT05827081 · Novartis · Phase 3 · live · background · “Goserelin” · registered Apr 2023
- NCT05607004 · Atossa Therapeutics, Inc. · Phase 2 · live · background · “goserelin” · registered Oct 2022
- NCT05161195 · Novartis · Phase 4 · live · background · “Goserelin” · registered Dec 2021
- NCT05110170 · Luye Pharma Group Ltd. · Phase 3 · comparator · “ZOLADEX® 3.6 mg” · registered Nov 2021
| AstraZeneca57% of its industry studiesUS: TerSera Therapeutics LLC (FDA 1989) | 34 studies | 34 studies | background 13 · comparator 2 |
AlpelisibRecent, repeatedEvidence- NCT05646862 · Hoffmann-La Roche · Phase 3 · live · comparator · “Alpelisib” · registered Dec 2022
- NCT05563220 · Menarini Group · Phase 2 · live · background · “Alpelisib” · registered Sep 2022
- NCT05501886 · Celcuity Inc · Phase 3 · live · comparator · “Alpelisib” · registered Aug 2022
- NCT03284957 · Sanofi · Phase 2 · background · “Alpelisib” · registered Sep 2017
| Novartis89% of its industry studiesUS: Novartis (FDA 2019)EU: Novartis (EMA 2020) | 33 studies | 33 studies | comparator 2 · background 2 |
sacituzumab govitecanRecent, repeatedEvidence- NCT07461454 · MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3 · live · comparator · “Sacituzumab govitecan” · registered Mar 2026
- NCT06827613 · Marengo Therapeutics, Inc. · Phase 2 · live · background · “Sacituzumab Govitecan (SG)” · registered Jan 2025
- NCT05867251 · Avenzo Therapeutics, Inc. · Phase 2 · live · background · “Sacituzumab Govitecan-hziy” · registered Apr 2023
- NCT04143711 · Dragonfly Therapeutics · Phase 2 · background · “Sacituzumab Govitecan-hziy” · registered Oct 2019
| Gilead Sciences77% of its industry studiesUS: IMMUNOMEDICS INC (FDA 2020)EU: Gilead Sciences (EMA 2021) | 33 studies | 33 studies | background 3 · comparator 1 |
capivasertibRecent, repeatedEvidence- NCT07287917 · Aminex Therapeutics, Inc. · Phase 2 · live · background · “Capivasertib” · registered Nov 2025
- NCT06982521 · Relay Therapeutics, Inc. · Phase 3 · live · comparator · “Capivasertib” · registered May 2025
- NCT05563220 · Menarini Group · Phase 2 · live · background · “Capivasertib” · registered Sep 2022
| AstraZeneca100% of its industry studiesUS: AstraZeneca (FDA 2023)EU: AstraZeneca (EMA 2024) | 33 studies | 33 studies | comparator 1 · background 2 |
olaparibRecent, repeatedEvidence- NCT06966700 · Merck & Co., Inc · Phase 3 · live · background · “Olaparib” · registered May 2025
- NCT06829199 · Merck & Co., Inc · Phase 2 · background · “Olaparib (if approved/available locally)” · registered Feb 2025
- NCT06797635 · Merck & Co., Inc · Phase 2 · live · background · “Olaparib” · registered Jan 2025
- NCT06065059 · Tango Therapeutics, Inc. · Phase 2 · background · “Olaparib” · registered Sep 2023
- NCT05700669 · Valerio Therapeutics · Phase 2 · background · “Olaparib” · registered Dec 2022
| AstraZeneca76% of its industry studiesUS: AstraZeneca (FDA 2017)EU: AstraZeneca (EMA 2014) | 35 studies | 12 studies | background 6 |
BevacizumabRecent, repeatedEvidence- NCT06271837 · AstraZeneca · Phase 2 · live · background · “Bevacizumab” · registered Jan 2024
- NCT05579366 · Genmab · Phase 2 · live · background · “Bevacizumab” · registered Oct 2022
- NCT03961698 · Infinity Pharmaceuticals, Inc. · Phase 2 · live · background · “Bevacizumab” · registered Apr 2019
- NCT02734004 · AstraZeneca · Phase 2 · live · background · “Bevacizumab” · registered Mar 2016
- NCT00868634 · iOMEDICO AG · Phase 3 · background · “bevacizumab” · registered Mar 2009
| Hoffmann-La Roche48% of its industry studiesUS: Hoffmann-La Roche (FDA 2004) + 6 othersEU: Hoffmann-La Roche (EMA 2005) + 7 others | 22 studies | 34 studies | background 9 · comparator 2 |
tucatinibRecent, repeatedEvidence- NCT07413939 · Hoffmann-La Roche · Phase 3 · live · comparator · “Tucatinib” · registered Feb 2026
- NCT06686394 · Merck & Co., Inc · Phase 2 · live · background · “Tucatinib” · registered Nov 2024
- NCT05091528 · Silverback Therapeutics · Phase 2 · background · “tucatinib” · registered Oct 2021
| Pfizer84% of its industry studiesUS: Pfizer (FDA 2020)EU: Pfizer (EMA 2021) | 22 studies | 22 studies | background 2 · comparator 1 |
osimertinibRecent, repeatedEvidence- NCT06618287 · Bristol-Myers Squibb · Phase 2 · live · background · “Osimertinib” · registered Sep 2024
- NCT05785741 · DualityBio Inc. · Phase 2 · live · background · “Osimertinib” · registered Mar 2023
| AstraZeneca93% of its industry studiesUS: AstraZeneca (FDA 2015)EU: AstraZeneca (EMA 2016) | 22 studies | 22 studies | background 2 |
elacestrantRecent, repeatedEvidence- NCT06938711 · Context Therapeutics Inc. · Phase 2 · background · “Elacestrant” · registered May 2023
- NCT05618613 · Context Therapeutics Inc. · Phase 2 · background · “Elacestrant” · registered Nov 2022
- NCT05573126 · Ellipses Pharma · Phase 2 · live · background · “Elacestrant” · registered Oct 2022
| Menarini Group75% of its industry studiesUS: Menarini Group (FDA 2023)EU: Menarini Group (EMA 2023) | 23 studies | 11 study | background 3 |